

Recent Posts
- Innate Killer Summit
- ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
- ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
- ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
- ASCO Genitourinary Cancers Symposium 2023